ERβ-mediated induction of cystatins results in suppression of TGFβ signaling and inhibition of triple-negative breast cancer metastasis
Author(s) -
Jordan Reese,
Elizabeth S. Bruinsma,
Adam W Nelson,
Igor Chernukhin,
Jason S. Carroll,
Ying Li,
Malayannan Subramaniam,
Vera J. Suman,
Vivian Negron,
David G. Monroe,
James N. Ingle,
Matthew P. Goetz,
John R. Hawse
Publication year - 2018
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.1807751115
Subject(s) - triple negative breast cancer , estrogen receptor , breast cancer , cancer research , transcriptome , estrogen receptor alpha , cystatin , metastasis , medicine , cancer , oncology , biology , gene expression , cystatin c , gene , genetics , renal function
Significance Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer and patients exhibit high rates of recurrence and mortality in part due to lack of treatment options beyond standard-of-care chemotherapy regimens. In the subset of TNBCs that express estrogen receptor beta (ERβ), ligand-mediated activation of ERβ elicits potent anticancer effects. We report here the elucidation of the ERβ cistrome and transcriptome in TNBC and identify a mechanism whereby ERβ induces cystatin gene expression resulting in inhibition of canonical TGFβ signaling and a blockade of metastatic phenotypes. These findings suggest that ERβ-targeted therapies represent a treatment option for the subset of women with ERβ-expressing TNBC.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom